Is there a risk of death, secondary cancers, or autoimmune disorders associated with the treatment?
In studies where MyVax® Personalized Immunotherapy has been used to treat patients with NHL, there have been no treatment-related deaths. There have been a few reports of new cancers or autoimmune disorders, but it is difficult to determine if these were related to the use of MyVax® Personalized Immunotherapy, because these patients also received other medications, such as chemotherapy. Monitoring for these risks in patients in the NHL study is ongoing, and these types of risks will also be monitored in this study.
